Skip to main content
Stemline's blood cancer drug accepted under priority review status

The FDA accepted under priority review Stemline Therapeutics' biologics license application for Elzonris, or tagraxofusp, being developed as a treatment for patients with blastic plasmacytoid dendritic cell neoplasm, with an action date of Feb. 21, 2019. A midstage trial showed that the drug prompted a 54% complete response rate in 13 patients.

Full Story: